ClinicalTrials.gg
CompletedNCT00424463Updated Jul 21, 2026Results posted

Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)

A Phase 3 interventional study of MCI-186 and Placebo of MCI-186 in Amyotrophic Lateral Sclerosis (ALS), sponsored by Shionogi. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Shionogi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan — 2 open to participants now, 4 under way, 2 of them phase 3. Amyotrophic Lateral Sclerosis · Japan.

Enrollment
7th of 20
181 · median 136
Started
2007
with 1 other
Phase 3
8 of 21
none open now
Registered
1st of 21
by date
Lead sponsor
3 of 21
Shionogi

Among the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, this one is the 7th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2007, is one of 8 in phase 3, and was the 1st registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

2 of the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, or all of them as a file.
02

Study summary

This is a long-term, double-blind, placebo-controlled study of MCI-186 to treat ALS. This study is the long-term extension of Study NCT00330681; Study NCT00330681 is a Phase 3, randomized, double-blind, placebo control, parallel assignment, 24-week study in the treatment of ALS. The objectives of this study are to assess the efficacy and safety of long-term intermittent therapy with 60 mg MCI-186 to ALS patients.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis (ALS)

Keywords

  • Amyotrophic lateral sclerosis (ALS)
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who ware completed drug administration without discontinuation in the preceding confirmatory study NCT00330681.

Exclusion criteria

Exclusion Criteria:

  • Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of to edaravone.
  • Patients whose is 50mL/min or less at the time of completion of drug administration in the study NCT00330681.
  • Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to .
  • Patients who are participating in other clinical trials except the study NCT00330681.
  • In addition to the above exclusion criteria, patients judged to be inadequate to participate in this study by their physician.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    1

    Drug: MCI-186

  • Placebo comparator
    2

    Drug: Placebo of MCI-186

Interventions

  • Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days ) - observation (14 days) cycle is repeated eight times.

    Also known as: Edaravone, Radicut

  • DrugPlacebo of MCI-186

    Two ampoules of placebo injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated eight times.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks

    0=worst; 48=best To investigate the sustainability of effects of edaravone, the analysis focusing on the comparison between the placebo and edaravone groups of patients who had received 6 cycles of edaravone treatment, i.e., the comparison of data from Cycles 7 to 12 between the edaravone-edaravone group and the edaravone-placebo group, was performed.

    Time frame: baseline (seventh cycle) and at 24 week (twelfth cycle)

Secondary outcomes

  1. Number of Participants With Death or a Specified State of Disease Progression

    Any of "death, disability of independent ambulation, loss of upper arm function, tracheotomy, use of respirator, and use of tube feeding" was defined as an event.

    Time frame: 24 weeks (from seventh cycle to twelfth cycle)

  2. Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks

    To investigate the sustainability of effects of edaravone, the analysis focusing on the comparison between the placebo and edaravone groups of patients who had received 6 cycles of edaravone treatment, i.e., the comparison of data from Cycles 7 to 12 between the edaravone-edaravone group and the edaravone-placebo group, was performed.

    Time frame: baseline (seventh cycle) and at 24 week (twelfth cycle)

  3. Percentage of Participants With Adverse Events

    Time frame: 36 weeks (from seventh cycle to fifteenth cycle)

  4. Percentage of Participants With Adverse Drug Reactions

    Time frame: 36 weeks (from seventh cycle to fifteenth cycle)

  5. Percentage of Participants With Laboratory Tests for Which the Incidence of Abnormal Changes Was 5% or Higher in Either Group

    Time frame: 36 weeks (from seventh cycle to fifteenth cycle)

  6. Percentage of Participants With Abnormal Changes in Sensory Examinations

    Time frame: 36 weeks (from seventh cycle to fifteenth cycle)

07

Results

Posted Jun 4, 2018

Participant flow

Participant flow — Overall Study
MilestoneMCI-186 - Placebo of MCI-186MCI-186 - MCI-186Placebo of MCI-186 - MCI-186
Started454888
Completed383472
Not completed71416
Withdrew: Adverse event232
Withdrew: Physician decision022
Withdrew: Withdrawal by subject425
Withdrew: Tracheotomy due to worsening of als176
Withdrew: Patient's convenience001

Outcome measures

PrimaryChange From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks

0=worst; 48=best To investigate the sustainability of effects of edaravone, the analysis focusing on the comparison between the placebo and edaravone groups of patients who had received 6 cycles of edaravone treatment, i.e., the comparison of data from Cycles 7 to 12 between the edaravone-edaravone group and the edaravone-placebo group, was performed.

Time frame:
baseline (seventh cycle) and at 24 week (twelfth cycle)
Reported as:
Mean · units on a scale
Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks
units on a scaleMCI-186 - Placebo of MCI-186MCI-186 - MCI-186Placebo of MCI-186 - MCI-186
Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks-5.5 ± 4.6-4.2 ± 4-5.4 ± 4.5
SecondaryNumber of Participants With Death or a Specified State of Disease Progression

Any of "death, disability of independent ambulation, loss of upper arm function, tracheotomy, use of respirator, and use of tube feeding" was defined as an event.

Time frame:
24 weeks (from seventh cycle to twelfth cycle)
Reported as:
Count of participants · Participants
Number of Participants With Death or a Specified State of Disease Progression
ParticipantsMCI-186 - Placebo of MCI-186MCI-186 - MCI-186Placebo of MCI-186 - MCI-186
death111
disability of independent ambulation81120
loss of upper arm function357
tracheotomy002
use of respirator012
use of tube feeding118
SecondaryChange From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks

To investigate the sustainability of effects of edaravone, the analysis focusing on the comparison between the placebo and edaravone groups of patients who had received 6 cycles of edaravone treatment, i.e., the comparison of data from Cycles 7 to 12 between the edaravone-edaravone group and the edaravone-placebo group, was performed.

Time frame:
baseline (seventh cycle) and at 24 week (twelfth cycle)
Reported as:
Mean · percentage of FVC
Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks
percentage of FVCMCI-186 - Placebo of MCI-186MCI-186 - MCI-186Placebo of MCI-186 - MCI-186
Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks-10.6 ± 13.16-12.91 ± 14.97-10.54 ± 13.21
SecondaryPercentage of Participants With Adverse Events
Time frame:
36 weeks (from seventh cycle to fifteenth cycle)
Reported as:
Number · percentage of participant
Percentage of Participants With Adverse Events
percentage of participantMCI-186 - Placebo of MCI-186MCI-186 - MCI-186Placebo of MCI-186 - MCI-186
Percentage of Participants With Adverse Events97.891.792
SecondaryPercentage of Participants With Adverse Drug Reactions
Time frame:
36 weeks (from seventh cycle to fifteenth cycle)
Reported as:
Number · percentage of participant
Percentage of Participants With Adverse Drug Reactions
percentage of participantMCI-186 - Placebo of MCI-186MCI-186 - MCI-186Placebo of MCI-186 - MCI-186
Percentage of Participants With Adverse Drug Reactions4.410.410.2
SecondaryPercentage of Participants With Laboratory Tests for Which the Incidence of Abnormal Changes Was 5% or Higher in Either Group
Time frame:
36 weeks (from seventh cycle to fifteenth cycle)
Reported as:
Number · percentage of participant
Percentage of Participants With Laboratory Tests for Which the Incidence of Abnormal Changes Was 5% or Higher in Either Group
percentage of participantMCI-186 - Placebo of MCI-186MCI-186 - MCI-186Placebo of MCI-186 - MCI-186
White blood cell count11.14.210.2
Alanine aminotransferase06.34.5
Urinary glucose06.33.4
SecondaryPercentage of Participants With Abnormal Changes in Sensory Examinations
Time frame:
36 weeks (from seventh cycle to fifteenth cycle)
Reported as:
Number · percentage of participant
Percentage of Participants With Abnormal Changes in Sensory Examinations
percentage of participantMCI-186 - Placebo of MCI-186MCI-186 - MCI-186Placebo of MCI-186 - MCI-186
Numbness000
Staggering02.12.3
Vibratory sensation000

Adverse events

Collected over from baseline (seventh cycle) to 36 weeks (fifteenth cycle). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MCI-186 - Placebo of MCI-186—13/45 (28.9%)43/45 (95.6%)
MCI-186 - MCI-186—25/48 (52.1%)43/48 (89.6%)
Placebo of MCI-186 - MCI-186—39/88 (44.3%)74/88 (84.1%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventMCI-186 - Placebo of MCI-186MCI-186 - MCI-186Placebo of MCI-186 - MCI-186
DysphagiaGastrointestinal disorders6/459/4822/88
Musculoskeletal disorderMusculoskeletal and connective tissue disorders4/456/4810/88
Respiratory failureRespiratory, thoracic and mediastinal disorders2/456/486/88
Gait disturbanceGeneral disorders0/454/485/88
DyslaliaNervous system disorders1/450/486/88
DyspnoeaRespiratory, thoracic and mediastinal disorders2/453/482/88
Respiratory disorderRespiratory, thoracic and mediastinal disorders1/452/482/88
Muscular weaknessMusculoskeletal and connective tissue disorders0/451/483/88
PneumoniaInfections and infestations0/451/482/88
EnterocolitisGastrointestinal disorders1/450/480/88
Most frequent other events
Showing 10 of 145
Most frequent other events
EventMCI-186 - Placebo of MCI-186MCI-186 - MCI-186Placebo of MCI-186 - MCI-186
NasopharyngitisInfections and infestations12/4510/4828/88
Gait disturbanceGeneral disorders9/4510/4827/88
ConstipationGastrointestinal disorders8/4510/4820/88
ContusionInjury, poisoning and procedural complications7/453/488/88
InsomniaPsychiatric disorders3/455/487/88
PruritusSkin and subcutaneous tissue disorders1/451/488/88
DiarrhoeaGastrointestinal disorders1/453/486/88
Tinea pedisInfections and infestations3/453/484/88
ArthralgiaMusculoskeletal and connective tissue disorders3/450/482/88
Muscular weaknessMusculoskeletal and connective tissue disorders3/450/482/88

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MCI-186 - Placebo of MCI-186MCI-186 - MCI-186Placebo of MCI-186 - MCI-186Total
<=18 years0000
Between 18 and 65 years382962129
>=65 years7192652
Sex: Female, Male
Sex: Female, Male(Participants)MCI-186 - Placebo of MCI-186MCI-186 - MCI-186Placebo of MCI-186 - MCI-186Total
Female12223165
Male332657116
08

Study locations

1 site
  • National Hospital Organization Miyagi National Hospital
    Watari-gun, Miyagi, Japan
09

References and documents

Publications

  • WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):20-31. doi: 10.1080/21678421.2017.1362000. PubMed 28872918 ↗
  • Takahashi F, Takei K, Tsuda K, Palumbo J. Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):32-39. doi: 10.1080/21678421.2017.1361442. PubMed 28872914 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2007 to primary completion in May 2009, 28 months.

Results were first posted in Jun 2018, 9 years after primary completion.

Of 24 phase 3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 28 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2007
First posted
Jan 19, 2007
StartActual
Jan 31, 2007
Primary completionActual
May 31, 2009
CompletionActual
May 31, 2009
Results first posted
Jun 4, 2018
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00424463
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Jan 19, 2007
Start date
Jan 31, 2007
Primary completion
May 31, 2009
Completion
May 31, 2009
Results posted
Jun 4, 2018
Last update
Jul 21, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion